Allspring Global Investments
TBPH

Allspring Global Investments’s Theravance Biopharma TBPH Stock Holding History

Allspring Global Investments’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$189K Buy
11,117
+334
+3% +$5.53K ﹤0.01% 1668
2026
Q1 		$171K Buy
+10,783
New +$191K ﹤0.01% 1622
2024
Q4 		– Sell
-521
Closed -$4.2K – 2358
2024
Q3 		$4.2K Buy
+521
New +$4.51K ﹤0.01% 2203
2023
Q2 		– Sell
-7,631
Closed -$82.8K – 2832
2023
Q1 		$82.8K Sell
7,631
-7,720
-50% -$81.6K ﹤0.01% 2117
2022
Q4 		$172K Sell
15,351
-5,282
-26% -$55.5K ﹤0.01% 1869
2022
Q3 		$209K Buy
20,633
+2,547
+14% +$23.9K ﹤0.01% 1802
2022
Q2 		$163K Buy
18,086
+6,942
+62% +$64K ﹤0.01% 1883
2022
Q1 		$106K Buy
+11,144
New +$109K ﹤0.01% 2740

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Allspring Global Investments's TBPH Position: Q2 2026 in Review

Allspring Global Investments increased its Theravance Biopharma (TBPH) stake by 3.1% in Q2 2026, buying an estimated $5.53K and bringing the position to 11,117 shares worth $189K. The position accounts for ﹤0.01% of the portfolio, ranked #1668.

Allspring Global Investments first reported a position in TBPH in Q1 2022 and has held it in 8 quarters since. The position peaked at $209K in Q3 2022. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Allspring Global Investments held 11,117 shares of Theravance Biopharma worth $189K as of Q2 2026.
  • Allspring Global Investments bought 334 Theravance Biopharma shares in Q2 2026, an estimated $5.53K.
  • Theravance Biopharma made up ﹤0.01% of Allspring Global Investments's portfolio in Q2 2026, its #1668 holding.
  • Allspring Global Investments first reported a position in Theravance Biopharma in Q1 2022 and has held it in 8 quarters since.
  • Allspring Global Investments's Theravance Biopharma position peaked at $209K in Q3 2022.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Allspring Global Investments's 13F filing for Q2 2026, filed 13 Aug 2026.